MedTrace Logo

A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula

NCT03438266 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2019-08-05

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel using cannula in participants seeking correction of age-related volume deficit in the mid-face.

Conditions

  • Age-related Volume Deficit in the Mid-face

Interventions

DEVICE

JUVÉDERM VOLUMA® XC injectable gel with cannula

Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.

DEVICE

JUVÉDERM VOLUMA® XC injectable gel with needle

Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Steve Abrams · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-05
Primary Completion
2018-05-29
Completion
2018-08-02
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438266 on ClinicalTrials.gov